Individualised adjuvant treatment by molecular integrated risk profile is safe and effective for patients with high-intermediate risk endometrial cancer; it spared 46% of patients with a favourable profile from adjuvant treatment, and reduces both overtreatment and undertreatment.
[Articles] Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
The Lancet Oncology | | Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, Nienke Kuijsters, Stefan Kommoss, Friederike L A Koppe, Marlies E Nowee, Henrike Westerveld, Maria A A De Jong, Filip Frühauf, Jeltsje S Cnossen, Jan Willem M Mens, Jannet C Beukema, Cyrus Chargari, Charles Gillham, Ina M Jurgenliemk-Schulz, Katrien Vandecasteele, Moritz Hamann, Mandy Kiderlen, Annette Staebler, Hans W Nijman, Bastiaan G Wortman, Elefteria Asteinidou, Stephanie M de Boer, Wilbert B van den Hout, Karen W Verhoeven-Adema, Remi A Nout, Hein Putter, Tjalling Bosse, Carien L Creutzberg
Topics: skin-cancer, uterine-cancer, clinical-trials